Phototherapy for Immune Skin Conditions: UVB, PUVA, Laser Phototherapy

Clinical Overview

Phototherapy is a cornerstone treatment for moderate-to-severe psoriasis, vitiligo, atopic dermatitis, lichen planus, and mycosis fungoides. Three primary modalities are used: narrowband UVB (NB-UVB, 311-313 nm), oral psoralen plus UVA (PUVA), and excimer laser (308 nm). All utilize ultraviolet radiation to induce immunosuppression, promote apoptosis of pathogenic T cells, increase regulatory T cells, and promote skin healing. NB-UVB is most commonly used due to favorable efficacy-to-risk ratio; PUVA is less favored but remains useful for certain conditions; excimer laser provides targeted treatment for localized disease.

Mechanisms of Phototherapy

Phototherapy induces multiple immune effects: (1) Direct keratinocyte apoptosis via DNA damage, reducing hyperplasia; (2) T cell apoptosis, particularly of pathogenic CD8+ and CD4+ effector cells; (3) Shift from Th1/Th17 to tolerogenic T regulatory cells (Tregs); (4) Production of immunosuppressive cytokines (IL-10, TGF-β); (5) Induction of aryl hydrocarbon receptor (AhR) signaling in immune cells, promoting anti-inflammatory responses. The therapeutic window is narrow: insufficient doses lack efficacy, while excessive exposure increases malignancy and photoaging risks.

Narrowband UVB (NB-UVB) Phototherapy

Mechanism and Efficacy

NB-UVB emits wavelengths of 311-313 nm, optimal for T cell suppression while minimizing erythema and systemic photoimmune effects. PASI-75 is achieved in 75% of patients with psoriasis after 24-30 treatments (typically 2-3 times weekly for 12-16 weeks). Superior to PUVA in head-to-head trials with lower carcinogenicity risk.

Dosing Protocols

Standard regimen: 2-3 treatments per week, with 24-48 hours between treatments. Starting dose: 50-70% of minimal erythema dose (MED). MED determined by exposure of small test areas to increasing UVB doses until erythema appears 24 hours later.

Dose escalation: After each treatment, increase dose by 10-20% if no erythema, or keep dose constant if mild erythema present. Maximum dose typically 2.5-4.0 J/cm² depending on protocol. Treatment duration: 12-16 weeks to assess response.

Maintenance therapy: Once PASI-75 achieved, maintenance is typically 1-2 treatments per week. Long-term phototherapy (years) is feasible with appropriate monitoring.

Clinical Applications

Plaque psoriasis: PASI-75 in 70-75% at 16 weeks. Effective for generalized disease.

Atopic dermatitis: PASI-75 equivalent (EASI-75) in 60-70%. Useful for moderate-to-severe AD unresponsive to topicals.

Vitiligo: Repigmentation in 75% with combination NB-UVB + topical corticosteroids or calcineurin inhibitors. Better response in facial/truncal vitiligo compared to acral sites.

Lichen planus: PASI-equivalent improvement in >70% with 12-20 treatments.

Mycosis fungoides (cutaneous T-cell lymphoma): Useful for early-stage (patch/plaque) disease; CR/PR in 50-80% depending on disease extent.

Safety Profile

Acute adverse effects: Erythema, pruritus, blistering (if overdosed), photosensitivity with psoralens (if concurrent use). Symptomatically managed with topical steroids, moisturizers, sunscreen.

Long-term carcinogenicity: Cumulative UVB exposure increases non-melanoma skin cancer risk (NMSC). Estimated risk: 1 additional NMSC per 1000 treatments after cumulative dose >300 J/cm². Melanoma risk appears lower than PUVA but still modestly elevated compared to no therapy. Estimated absolute risk increase: 0.5-1 case per 1000 patient-years.

Photoaging: Chronic phototherapy causes photoaging (wrinkles, elastosis, dyspigmentation), preventable with high-SPF sunscreen and photoprotection.

Cataracts: Rare with proper eye protection; UVB does not penetrate to lens with closed eyes and eyelid protection.

Baseline Assessment and Monitoring

Baseline: Full skin exam documenting extent and severity; baseline photos useful. Obtain baseline dermatoscopy or polarized dermoscopy if >20 atypical nevi present (increased melanoma risk baseline). For patients with extensive actinic damage or history of skin cancer, phototherapy contraindications may exist or require specialist consultation.

Monitoring: Clinical exam before each treatment to assess erythema and adjust dose. Annual or biennial full-body skin exam and photo documentation. Dermatoscopy of atypical nevi if present. Consider periodic skin cancer screening (dermatoscopy or dermoscopy) for high-risk patients.

PUVA (Psoralen + UVA) Therapy

Mechanism and Efficacy

PUVA combines oral or topical psoralens (8-methoxypsoralen) with UVA (320-400 nm) exposure. Psoralens absorb UVA energy, undergo photochemical reactions, and form adducts with DNA, causing T cell apoptosis. PASI-75 achieved in 70% of psoriasis patients, similar to NB-UVB but with higher carcinogenicity. Less commonly used than NB-UVB due to superior safety profile of NB-UVB.

Dosing

Oral PUVA: 8-methoxypsoralen 0.6 mg/kg, taken 1.5-2 hours before UVA exposure. UVA dose: 0.5-2 J/cm² initially, escalated by 0.5-1 J/cm² per treatment. Typical regimen: 2-3 times per week.

Topical PUVA: 0.75% 8-methoxypsoralen lotion applied 15 minutes before UVA exposure; useful for localized disease (hands, feet).

Safety Considerations

Phototoxicity: PUVA causes more pronounced erythema and blistering than NB-UVB; photosensitivity reactions more common.

Carcinogenicity: Cumulative PUVA exposure significantly increases NMSC risk (estimated 1 NMSC per 100 treatments after high cumulative doses). Melanoma risk also elevated compared to NB-UVB. Long-term PUVA use (>1000 treatments or cumulative dose >3000 J/cm²) strongly associated with NMSC and melanoma; thus, PUVA is typically limited to short courses.

Cataracts: Psoralens concentrate in the lens; mandatory eye protection (UV-blocking sunglasses) is essential. Cases of cataracts have been reported with PUVA, particularly with inadequate eye protection.

Drug interactions: Psoralens interact with many medications (tetracyclines, thiazides, NSAIDs, antimalarials); these can cause photosensitivity and should be avoided or used with caution.

Excimer Laser (308-nm) Phototherapy

Mechanism

The 308-nm excimer laser (xenon-chloride) emits monochromatic light at a wavelength that optimally induces T cell apoptosis. Provides targeted phototherapy for localized plaques without exposing uninvolved skin.

Efficacy and Applications

PASI-75 response: 80-90% for localized plaques after 12-20 treatments. Particularly useful for: hands, feet, scalp, genitals (where systemic phototherapy may not treat well or where patients prefer localized approach). Can be combined with topical agents or systemic therapy.

Dosing

Starting dose: 25-50 mJ/cm² per pulse, with 3-6 pulses per site. Escalation in 25-50 mJ increments per session based on erythema response. Treatments typically 2 times per week.

Safety

Safety profile superior to broadband UVB or PUVA due to narrow wavelength and localized application. Systemic carcinogenicity risk minimal. Local adverse effects: temporary erythema, occasionally blistering if overdosed. No systemic absorption; therefore, no phototoxicity from drug interactions.

Phototherapy Combination Strategies

NB-UVB + topical/systemic agents: Combination enhances efficacy. NB-UVB + topical corticosteroids or calcineurin inhibitors (especially for vitiligo, lichen planus, atopic dermatitis) yields superior outcomes to monotherapy.

NB-UVB + acitretin: Acitretin increases skin photosensitivity; combination yields improved efficacy for psoriasis (PASI-75 in 80% vs 70% with NB-UVB alone) but requires lower UVB doses to avoid excessive erythema.

NB-UVB + biologic agents: Combining phototherapy with biologics is feasible, though less commonly done. Some data suggest synergy, but biologic efficacy alone often makes phototherapy unnecessary.

When to Choose Which Modality

NB-UVB: First-line phototherapy choice for most conditions (psoriasis, AD, lichen planus, vitiligo). Safe, effective, accessible.

PUVA: Limited current use; reserved for mycosis fungoides or patients with specific indications; avoided when NB-UVB available due to higher carcinogenicity.

Excimer laser: First-line for localized plaques (scalp, hands, feet, genitals). Often preferred by patients who wish to avoid whole-body phototherapy.

Contraindications and Caution

Absolute contraindications: History of melanoma or extensive NMSC (relative—specialist judgment needed), photosensitizing medications (tetracyclines, thiazides, NSAIDs, antimalarials; can be held or managed), active infection (compromised immune function; wait until resolved).

Relative cautions: Extensive actinic damage baseline, >20 atypical nevi, immunosuppression (MTX, biologics; phototherapy still feasible but warrants closer monitoring).

Patient Education and Photoprotection

Patients must understand that phototherapy induces immune suppression and carries carcinogenicity risk. Strict sunscreen use (SPF ≥30, broad-spectrum) on days of treatment and daily thereafter is essential. UV protective clothing, hats, and sunglasses during phototherapy and outdoor activities. Eye protection mandatory for PUVA. Baseline and periodic skin examinations essential. Educate patients on skin self-examination and signs of skin cancer (new moles, growth, asymmetry, irregularity, color variation, size >6mm).

When to Refer

Refer for phototherapy if moderate-to-severe disease, specialist phototherapy equipment needed, or if complex decisions regarding phototherapy modality and duration required.

FAQ

Will phototherapy increase my skin cancer risk?

Yes, phototherapy increases non-melanoma skin cancer risk (basal cell and squamous cell carcinomas), particularly with cumulative high doses and long-term use. Estimated risk: approximately 1 additional skin cancer per 1000 treatments after very high cumulative doses. Melanoma risk is also modestly increased but lower than with PUVA. Risk is substantially lower with NB-UVB compared to PUVA. Strict sunscreen use (SPF ≥30), protective clothing, and regular skin checks reduce overall carcinogenicity risk. For many patients with severe psoriasis, phototherapy's benefit outweighs this risk, particularly if used for limited duration (weeks to months).

Can I use phototherapy if I'm on biologics?

Yes, phototherapy can be combined with biologic therapy, though biologics alone often provide sufficient efficacy that phototherapy becomes unnecessary. Combination use is safe but carries additive immunosuppression risk; monitor for infections. If a biologic is providing good disease control, phototherapy is typically not needed. However, if biologic efficacy is partial or if localized plaques persist, adding phototherapy (especially excimer laser for localized areas) can be beneficial.

How long until I see improvement with phototherapy?

Timeline varies by modality and disease. NB-UVB typically shows 25-50% improvement by week 4-6, with PASI-75 by week 12-16. Excimer laser for localized plaques shows improvement by 4-6 treatments (2 weeks). PUVA onset is similar to NB-UVB. Continuation beyond 16-20 weeks for NB-UVB rarely yields additional benefit; if PASI-75 not achieved by then, consider adding topical agents, systemic therapy, or switching to biologic. Once clearance achieved, maintenance phototherapy (1-2 times per week) can prolong remission.

What are the long-term risks? Can I use phototherapy forever?

Long-term phototherapy (years to decades) carries cumulative carcinogenicity risk. PUVA is not recommended long-term due to high carcinogenicity; if used, cumulative doses >3000 J/cm² warrant cessation. NB-UVB carries lower risk but still warrants periodic monitoring and skin exams. Indefinite maintenance phototherapy is not typically recommended; rather, treatment cycles (weeks to months) followed by maintenance intervals or de-escalation to less frequent treatments (monthly or quarterly) are typical. As biologics have improved, many dermatologists now use phototherapy for short-term intensive courses rather than indefinite maintenance, reducing cumulative carcinogenicity risk.

References